Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial

In the ALCYONE trial, daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) reduced the risk of disease progression or death by 50% versus bortezomib, melphalan, and prednisone (VMP) in patients with transplant-ineligible newly diagnosed multiple myeloma. Here, we report a subanalysis of Ea...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Hematol
Autors principals: Fujisaki, Tomoaki, Ishikawa, Takayuki, Takamatsu, Hiroyuki, Suzuki, Kenshi, Min, Chang-Ki, Lee, Jae Hoon, Wang, Jianping, Carson, Robin, Crist, Wendy, Qi, Ming, Nagafuji, Koji
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6900260/
https://ncbi.nlm.nih.gov/pubmed/31620815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-019-03794-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars